Regeneveda - The Beverly Hills Institute Of Cellular Therapy

Owner: Thom Lobe
Acct #379890
← Search results
1
Total Licenses
0
Active
0
Locations
2013
Operating Since

Is this your business? — verify your email to help keep this page accurate.

Business Summary

Regeneveda - The Beverly Hills Institute Of Cellular Therapy has been operating in Chicago since 2013 (~13 years). They currently hold 0 active licenses (1 total on file) across 0 locations in RUSH & DIVISION.

Primary activity: Miscellaneous Personal Services | Retail Sales of General Merchandise and Non-Perishable Food (Convenience Store).

Most recent activity: lapse on 2021-02-24.

Locations

1 address on file
  • 1 E DELAWARE PL 3RD 306Near North Side · 1 licenseInactive
    Licenses (1)
    • Limited Business License2021-02-24

Activities

Miscellaneous Personal Services | Retail Sales of General Merchandise and Non-Perishable Food

Licenses

1 record

One row per license event since 2020. Tap any row for the full record. A renewal with no issuance below it points to a license first issued before our 2020 coverage window.

Limited Business LicenselapseIssued 2021-02-24 · Expires 2023-04-15
License number
2390580
License code
1010
Site number
2
DBA name
Regeneveda - The Beverly Hills Institute Of Cellular Therapy
Legal name
Rejuveneda Medical Group, INC.
Address
1 E DELAWARE PL 3RD 306, CHICAGO, IL 60611
Business activity
Miscellaneous Personal Services | Retail Sales of General Merchandise and Non-Perishable Food
Application type
RENEW
Conditional approval
N
License start
2021-04-16
Payment date
2021-02-23
Date issued
2021-02-24
Expiration
2023-04-15
Status change
Data not available
Ward
42
Precinct
32
Police district
18
Community area
Near North Side
Neighborhood
RUSH & DIVISION
SSA
Data not available

Permits & Construction

Data not available

Property & Census

Neighborhood

Median household income
$122,659
Owner-occupied housing
45.6%
Bachelor’s degree or higher
81.6%
People per sq mi
62,146
White-collar workforce
72.3%
Census tract 17031081201 · ACS 5-year 2024

Related